{"id":"NCT00095056","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)","officialTitle":"Sitagliptin Study in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-10","primaryCompletion":"2006-07","completion":"2006-07","firstPosted":"2004-11-01","resultsPosted":"2010-07-23","lastUpdate":"2015-04-02"},"enrollment":91,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2","Chronic Renal Insufficiency"],"interventions":[{"type":"DRUG","name":"sitagliptin","otherNames":["MK0431"]},{"type":"DRUG","name":"Placebo to Sitagliptin","otherNames":[]},{"type":"DRUG","name":"glipizide","otherNames":[]},{"type":"DRUG","name":"Placebo to glipizide","otherNames":[]}],"arms":[{"label":"Sitagliptin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function).","primaryOutcome":{"measure":"Safety and Tolerability of Sitagliptin After 12 Weeks of Treatment","timeFrame":"Week 0 through Week 12","effectByArm":[{"arm":"Sitagliptin","deltaMin":41,"sd":null},{"arm":"Placebo","deltaMin":16,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["18518892"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":65},"commonTop":["Diarrhoea","Upper Respiratory Tract Infection","Hypoglycaemia","Urinary Tract Infection","Blood Glucose Increased"]}}